SC Bio Accelerates AI-Driven Liver Cancer Drug Development Under Government Project
AI TIMES ·
✦ AI Summary
According to AI TIMES, SC Bio was selected on September 1 as the lead institution for the "2026 Pharmaceutical and Bio Venture Collaboration…
According to AI TIMES, SC Bio was selected on September 1 as the lead institution for the "2026 Pharmaceutical and Bio Venture Collaboration-Based Technology Development Project," and will now accelerate AI-based liver cancer drug development. The company said it aims to identify a liver cancer treatment candidate targeting a new target within 24 months. The selection is significant in that the company's development system, which combines infrastructure that can handle the full preclinical process in-house with accumulated empirical data, passed the government review. SC Bio plans to boost the speed and accuracy of candidate discovery through a cyclical research approach that feeds results from design, synthesis, cell and animal tests, and analysis back into learning. In particular, the strategy targets new mechanisms to address the limitations of resistance in existing therapies, underscoring a shift in approach rather than a simple improvement in development efficiency. The article also outlines the company's blueprint for tightly linking AI with real-world laboratories based on large-scale synthesis capabilities and its own experimental foundation.
Perspective
The key point here is not just using AI as an auxiliary tool, but proving a closed-loop development structure, where actual experiments and learning are intertwined, as a source of business competitiveness. Now that the government project selection has confirmed that possibility, the focus will likely be on how quickly the company can turn candidate compounds into verifiable results. In the industry as well, this is seen as another example showing that success in drug development depends less on the algorithm itself and more on the combined strength of data and experimental infrastructure supporting it.
This perspective is BizCrush's own commentary and is not part of the reporting by AI TIMES.
This article was produced with the help of an automated content generation algorithm.
Source: AI TIMES
View originalThis article was summarized and organized by BizCrush based on the original article from AI TIMES. For exact quotations and full details, please refer to the original article.